Nanoparticle Albumin-bound Paclitaxel As Neoadjuvant Chemotherapy of Breast Cancer: a Systematic Review and Meta-analysis

Overview

Journal Oncotarget

Specialty Oncology

Date 2017 Jan 7

PMID 28061451

Citations 30

Authors

Yu Zong

Jiayi Wu

Kunwei Shen

Affiliations

Soon will be listed here.

Abstract

Background: The value of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in neoadjuvant systemic therapy for breast cancer remains uncertain.

Methods: Both electronic databases and proceedings of oncologic meetings were included in systematic literature search. Pooled rates of pathological complete response (pCR), odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using fixed-effect or random-effect model to determine the effect of neoadjuvant nab-paclitaxel.

Results: Twenty-one studies with 2357 patients were included, 3 of which were randomized clinical trials. The aggregate pCR(ypT0/is ypN0) rate was 32% (95% CI 25-38%) in unselected breast cancer patients and variated in different subtypes. Within randomized clinical trials, the probability of achieving pCR was significantly higher in the nab-paclitaxel group than in the conventional taxanes group (OR = 1.383, 95%CI 1.141-1.676, p = 0.001). For non-hematological toxic effect, any grade and grade 3-4 peripheral sensory neuropathy occurred more frequently with nab-paclitaxel compared to paclitaxel (any grade, OR = 2.090, 95%CI 1.016-4.302, p = 0.045; grade3-4, OR = 3.766, 95%CI 2.324-6.100, p < 0.001). Hypersensitivity was more common with paclitaxel than nab-paclitaxel at any grade and grade 3-4.

Conclusion: nab-paclitaxel is an effective cytotoxic drug in neoadjuvant treatment of breast cancer, especially for aggressive tumors in terms of pCR. Exchange of nab-paclitaxel for conventional taxanes could significantly improve pCR rate with reasonable toxicities.

Citing Articles

Unveiling the Hidden Risks: An Update Decade-Long Analysis of Abraxane-Related Adverse Events from the FAERS Database.

Zhao Y, Li X, Wang C, Jiao Y, Shen Y, Wang T Int J Nanomedicine. 2024; 19:11847-11858.

PMID: 39558918 PMC: 11572439. DOI: 10.2147/IJN.S490400.

Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO/NCCES01 trial.

Qin J, Xue L, Hao A, Guo X, Jiang T, Ni Y Nat Med. 2024; 30(9):2549-2557.

PMID: 38956195 PMC: 11405280. DOI: 10.1038/s41591-024-03064-w.

Pharmaceutical Applications of Biomass Polymers: Review of Current Research and Perspectives.

Bejenaru C, Radu A, Segneanu A, Bita A, Ciocilteu M, Mogosanu G Polymers (Basel). 2024; 16(9).

PMID: 38732651 PMC: 11085205. DOI: 10.3390/polym16091182.

A meta-analysis of the incidence and risk of skin toxicity with nab-paclitaxel and paclitaxel in cancer treatment.

Li H, Wang W, Wang Z Am J Transl Res. 2023; 15(6):4279-4290.

PMID: 37434856 PMC: 10331690.

Targeting unfolded protein response using albumin-encapsulated nanoparticles attenuates temozolomide resistance in glioblastoma.

Kiang K, Tang W, Song Q, Liu J, Li N, Lam T Br J Cancer. 2023; 128(10):1955-1963.

PMID: 36927978 PMC: 10147657. DOI: 10.1038/s41416-023-02225-x.

References

Shigematsu H, Kadoya T, Masumoto N, Sasada T, Emi A, Ohara M . The efficacy and safety of preoperative chemotherapy with triweekly abraxane and cyclophosphamide followed by 5-Fluorouracil, epirubicin, and cyclophosphamide therapy for resectable breast cancer: a multicenter clinical trial. Clin Breast Cancer. 2014; 15(2):110-6. DOI: 10.1016/j.clbc.2014.09.010. View

Kuwayama T, Nakamura S, Hayashi N, Takano T, Tsugawa K, Sato T . Randomized Multicenter Phase II Trial of Neoadjuvant Therapy Comparing Weekly Nab-paclitaxel Followed by FEC With Docetaxel Followed by FEC in HER2 Early-stage Breast Cancer. Clin Breast Cancer. 2018; 18(6):474-480. DOI: 10.1016/j.clbc.2018.06.012. View

von Minckwitz G, Schneeweiss A, Loibl S, Salat C, Denkert C, Rezai M . Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol. 2014; 15(7):747-56. DOI: 10.1016/S1470-2045(14)70160-3. View

Amoroso V, Generali D, Buchholz T, Cristofanilli M, Pedersini R, Curigliano G . International Expert Consensus on Primary Systemic Therapy in the Management of Early Breast Cancer: Highlights of the Fifth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2013). J Natl Cancer Inst Monogr. 2015; 2015(51):90-6. PMC: 5009414. DOI: 10.1093/jncimonographs/lgv023. View

Robidoux A, Buzdar A, Quinaux E, Jacobs S, Rastogi P, Fourchotte V . A phase II neoadjuvant trial of sequential nanoparticle albumin-bound paclitaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide in locally advanced breast cancer. Clin Breast Cancer. 2010; 10(1):81-6. DOI: 10.3816/CBC.2010.n.011. View

Lobo C, Lopes G, Baez O, Castrellon A, Ferrell A, Higgins C . Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer. Breast Cancer Res Treat. 2010; 123(2):427-35. DOI: 10.1007/s10549-010-1002-0. View

Desai N, Trieu V, Yao Z, Louie L, Ci S, Yang A . Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res. 2006; 12(4):1317-24. DOI: 10.1158/1078-0432.CCR-05-1634. View

Gianni L, Mansutti M, Anton A, Calvo L, Bisagni G, Bermejo B . Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2-Negative Breast Cancer-The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial: A Randomized Phase 3 Clinical Trial. JAMA Oncol. 2018; 4(3):302-308. PMC: 5885830. DOI: 10.1001/jamaoncol.2017.4612. View

Peto R, Davies C, Godwin J, Gray R, Pan H, Clarke M . Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet. 2011; 379(9814):432-44. PMC: 3273723. DOI: 10.1016/S0140-6736(11)61625-5. View

10.

Huang L, Chen S, Yao L, Liu G, Wu J, Shao Z . Phase II trial of weekly nab-paclitaxel and carboplatin treatment with or without trastuzumab as nonanthracycline neoadjuvant chemotherapy for locally advanced breast cancer. Int J Nanomedicine. 2015; 10:1969-75. PMC: 4362893. DOI: 10.2147/IJN.S77000. View

11.

Tremble P, Lane T, Sage E, Werb Z . SPARC, a secreted protein associated with morphogenesis and tissue remodeling, induces expression of metalloproteinases in fibroblasts through a novel extracellular matrix-dependent pathway. J Cell Biol. 1993; 121(6):1433-44. PMC: 2119706. DOI: 10.1083/jcb.121.6.1433. View

12.

Tanaka S, Iwamoto M, Kimura K, Matsunami N, Morishima H, Yoshidome K . Phase II Study of Neoadjuvant Anthracycline-Based Regimens Combined With Nanoparticle Albumin-Bound Paclitaxel and Trastuzumab for Human Epidermal Growth Factor Receptor 2-Positive Operable Breast Cancer. Clin Breast Cancer. 2015; 15(3):191-6. DOI: 10.1016/j.clbc.2014.12.003. View

13.

von Minckwitz G, Untch M, Blohmer J, Costa S, Eidtmann H, Fasching P . Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012; 30(15):1796-804. DOI: 10.1200/JCO.2011.38.8595. View

14.

Nahleh Z, Barlow W, Hayes D, Schott A, Gralow J, Sikov W . SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer. Breast Cancer Res Treat. 2016; 158(3):485-95. PMC: 4963434. DOI: 10.1007/s10549-016-3889-6. View

15.

Gradishar W, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P . Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005; 23(31):7794-803. DOI: 10.1200/JCO.2005.04.937. View

16.

Roy V, LaPlant B, Gross G, Bane C, Palmieri F . Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane) in combination with gemcitabine in patients with metastatic breast cancer (N0531). Ann Oncol. 2008; 20(3):449-53. PMC: 2733073. DOI: 10.1093/annonc/mdn661. View

17.

Schneeweiss A, Seitz J, Smetanay K, Schuetz F, Jaeger D, Bachinger A . Efficacy of nab-paclitaxel does not seem to be associated with SPARC expression in metastatic breast cancer. Anticancer Res. 2014; 34(11):6609-15. View

18.

Untch M, Jackisch C, Schneeweiss A, Conrad B, Aktas B, Denkert C . Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial. Lancet Oncol. 2016; 17(3):345-356. DOI: 10.1016/S1470-2045(15)00542-2. View

19.

Robidoux A, Tang G, Rastogi P, Geyer Jr C, Azar C, Atkins J . Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial. Lancet Oncol. 2013; 14(12):1183-92. DOI: 10.1016/S1470-2045(13)70411-X. View

20.

Dranitsaris G, Coleman R, Gradishar W . nab-Paclitaxel weekly or every 3 weeks compared to standard docetaxel as first-line therapy in patients with metastatic breast cancer: an economic analysis of a prospective randomized trial. Breast Cancer Res Treat. 2009; 119(3):717-24. DOI: 10.1007/s10549-009-0424-z. View